… treatment option for patients with AR to EGFR-TKIs is still cytotoxic chemotherapy. In the
absence of specific clinical studies exploring what is the most effective cytotoxic treatment in this …

… EGFR tyrosine kinase mutations [6, 7]. The identification of EGFR mutations leads to the
development of EGFR … confirmed EGFR mutation and patients with unknown or EGFR wild-type. …

… has progressed on their initial EGFR inhibitor, including therapies … treatment strategies
for patients with EGFR-mutant lung cancer whose disease progresses on their initial EGFR …

… EGFR-mutant lung cancer previously treated with erlotinib or gefitinib, documented progression
on EGFR … , radiofrequency ablation, or surgical treatment of a site of progressive disease. …

… In this review, we will summarize the mechanism of EGFR-TKI tolerance and present
treatment strategies to overcome resistance. There are several outstanding reviews so far [6,7,8,9], …

… Various clinical trials have demonstrated that EGFR inhibitors are clinically efficacious in the
… EGFR-TKIs impede phosphorylation of the intracellular tyrosine kinase component of EGFR …

… EGFR-mutated tumors tend to be dependent on EGFR activity … exists to treat such tumors
with oral tyrosine kinase inhibitors (… first-line treatment options for patients with EGFR mutation-…

… This becomes even more relevant when we consider the potential treatment options post-osimertinib.
Resistance mechanisms for osimertinib are currently not well understood and …

… -mutated NSCLC, but its role in patients harboring EGFR … available EGFR TKIs is critical to
guiding treatment decisions in … the treatment of NSCLC patients harboring uncommon EGFR …

… TKIs in EGFR-mutant NSCLC, examine current treatment standards, … EGFR-dependent
(involving secondary mutations in EGFR) and EGFR-independent (mutations that bypass EGFR …